Since 2022 health systems have faced a "tripledemic" of influenza, COVID-19 and RSV. The 2023–2024 respiratory season in the United States had about 1 million combined hospitalizations linked to these viruses.
Researchers describe a combined vaccine under development that delivers five viral proteins in one shot. The team used a platform called CoPoP and added two immune-stimulating ingredients, PHAD and QS-21, to increase potency.
Tests in mice, ferrets and cotton rats produced protective immune responses. The scientists found no clear immune interference, but they say more studies are needed. No vaccine that protects against all three viruses is yet approved.
Difficult words
- tripledemic — A time with three virus epidemics at once
- hospitalization — When a person is admitted to hospitalhospitalizations
- protein — A natural part of cells in living thingsproteins
- potency — How strong a medicine or vaccine is
- interference — When one immune response affects another response
- approve — To officially allow or accept somethingapproved
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Have you or someone you know had flu, COVID-19, or RSV? What happened?
- Would you want a single vaccine for several viruses? Why or why not?
- Why do the scientists say more studies are needed for the combined vaccine?
Related articles
Affordable twice-yearly HIV injection lenacapavir to reach 120 countries
Lenacapavir, a twice-yearly HIV prevention injection, will be licensed for 120 low- and middle-income countries at US$40 a year. Rollout is expected from 2027 with funding support, but some countries and price transparency remain concerns.
New Oral Drug Candidate for Measles and Parainfluenza
Researchers identified a clinical candidate called GHP-88310 that inhibits orthoparamyxoviruses and tested it in animal models and human airway cultures. The compound showed broad once-daily oral activity and good tolerance in animals.